ProCE Banner Activity

Expert Thoughts on Sequencing Therapy for Patients With HER2+ Metastatic Breast Cancer 

Clinical Thought

Are you up-to-date on current expert thoughts on optimal treatment sequencing for patients with HER2-positive metastatic breast cancer? Read this commentary to gain expert insights.

Released: January 29, 2025

Expiration: January 28, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Disclosure

Primary Author

Ian Krop, MD, PhD

Associate Cancer Center Director for Clinical Research
Medical Director, Clinical Trials Office
Yale Cancer Center
Chief Scientific Officer, Translational Breast Cancer Research Consortium
New Haven, Connecticut

Ian Krop, MD, PhD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Lilly, Novartis, Seagen; researcher: MacroGenics.

Sarah L. Sammons, MD

Assistant Professor
Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Sarah L. Sammons, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Novartis, Pfizer; researcher: AstraZeneca, Lilly, Relay, Seagen, Sermonix.